Evidence for SGLT-2 inhibitors: Usman et al. [74] conducted a systematic review and meta-analysis (15 studies, n=100952) and reported that SGLT-2 inhibitors reduced HHF by 28% in individuals with T2D and 28% in individuals with ASCVD. This evidence concerns the gene SLC5A2 and atherosclerosis.